9999999997-12-012430.txt : 20120806 9999999997-12-012430.hdr.sgml : 20120806 20120806142506 ACCESSION NUMBER: 9999999997-12-012430 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20120806 DATE AS OF CHANGE: 20120806 20120806 20120806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIROPHARMA INC CENTRAL INDEX KEY: 0000946840 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232789550 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-21699 FILM NUMBER: 121009401 BUSINESS ADDRESS: STREET 1: 730 STOCKTON DRIVE CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 6104587300 MAIL ADDRESS: STREET 1: 730 STOCKTON DRIVE CITY: EXTON STATE: PA ZIP: 19341 CT ORDER 1 filename1.pdf begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.,P94P`C$+`P<#7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)= M+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]087)E;G0@."`P(%(O4F5S;W5R8V5S M(#$V(#`@4B]2;W1A=&4@,"]4>7!E+U!A9V4^/@UE;F1O8FH-,3,@,"!O8FH- M/#PO1FEL=&5R+T9L871E1&5C;V1E+T9IR`/J)UTS;3E8%XS,BU.GS6^6YO+$]*R8WVT(BSB,P+M6M!!([A;%8?UZ,P MC&$DJ+3S43LXY='&H7-5YL73AS0O=0M+_1ONZU)5'QVV5*4F#K&`BZ^2T:PN MMHO4X8EIM,GV9%DWI2IP`N^.E_WB M,O:SV#NVLV#LA/D:Y"$\LGFO#*-+&5+Y-AG^58'!*PJ,^?L$^%;M<3K0'F?_ MH;VSX1[P_)OZ7JKQM.V^`IWN.A6AMOSFNUYV]WU->0RSO7=6WDMS>J.7M]-1 MQZ:O/-3UD.VI/^]A3O7>MUK\(\``)_")60T*96YDON%)?H#(LPZ?9-Z\_LLXV3F63JE)25=B,[:D( M>`=H-O^^=SX`VW&B]J&.8@9FYLR]YYYS\:>;-8%]-?B2##XEB0L$DMV`N.#@ M'UX\)X3(&=DC'Y+G@0-[_$^VXNME8`"8R5\XMHA-`DBF^$0\2'[6`\NSX[B? MM6S'(;'8K@`AGAT:OT^^CI)+`_1Q([(GZN(:O`;%6 M'V6*YWG^Q7F>6&/I$2[\C?'RUT/*GU-8%-N2'TN>UC333)V%^Z9`H1V>%M"8 MLYS"LK0!T2V7A$*0,)G_!&X4QZHZQ/;)Z98_KWWD2G2(KQPB>-,Z]'OE.^=Y M^5U>OF(43,N-`J=/T!PACSG;IC4K"VB*C')8 M-9B;ZV\L%SC];@8H]L;$+UK5K-BK>J`9A=LZBEU/A;(MBYWIVY[!,EK4+,7= MQ,BAYE0-ZVTPBCP M$$Z/G%;(E"2A@LTK]`6.D`4L,(:G.Q@&''H]$Z,6WM?P9RJH#VF-7ZP2K"L2 M0LUUESZB75>=+U5G?&_2G.T8K43JHNRZXCG>/#]3OA7#DB.KT@S8,L/@I)-H MZ19I(1?*.$1C#0VMWA-!BLK-.:59J>:@W+5Q*M@N4)&G3J@5SWA;#R&`!WMM M3VP(`O?)V#R93X;_9`XE\I3]S12%B*U#[(OV:%0"!4^<:/[$[9R)P"D<,/>, MUE169&2PHA>0!+O2T2TM5*2P*&LAQ&.S00?FKY"Q:IN7%47!VX"!8\4R=%PN M"0QL+^SK&W10@8KR=2@\DJ,SLKZHGN9`F\!3)MB5>5Z^=%:V%/2UWD=;N[RP M/`<1[H:B+G,J-8JA"S@9';Z2HSZZ-^)6*>+)JI@U4PJF6L%'REF955`=Z59H M*OOHMP5"/T/I19_3KX*'S?X*3_P;ND:O@7S7?;S M9/"/``,`"(0)\0T*96YDG)E4WI.5&-Z:V,Y M9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM M<'1K/2)!9&]B92!835`@0V]R92`U+C(M8S`P,2`V,RXQ,SDT,SDL(#(P,3`O M,#DO,C&UL.FQA;F<](G@M9&5F M875L="(^36EC&%P+S$N,"\B/@H@("`@("`@("`\>&UP.D-R96%T941A=&4^,C`Q M,BTP."TP-E0Q-#HR,CHS,2TP-#HP,#PO>&UP.D-R96%T941A=&4^"B`@("`@ M("`@(#QX;7`Z0W)E871O&UL;G,Z<&1F/2)H='1P.B\O M;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*("`@("`@("`@/'!D9CI0&UP34TZ26YS=&%N8V5)1#YU=6ED.C0X.3!E9&0V+6(T.&8M-#&UP34TZ26YS=&%N8V5)1#X*("`@("`@/"]R9&8Z M1&5S8W)I<'1I;VX^"B`@(#POJ'5!:DZ@Z%T].A&.P?F[&@*PY:JFT/,B=RK1.52RS2,KH9VU9=Y[( MOD,NC'-P15JV$G*AA>9)Z\W_24?>K!,2JR?RMS%`8Y=@G4,")842*0RLM[/Q MGV7@/+G8X)"U=I,7?P_0>S(0PT8DO2\*S:OJ*\``/?8_N`T*96YD7!E+UA2968O5ULQ(#(@,5T^/G-T